Influx Healthtech Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Influx Healthtech Ltd is ₹ 290.5 as of 15 May 15:30 . The P/E Ratio of Influx Healthtech Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Influx Healthtech Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Influx Healthtech Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Influx Healthtech Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Influx Healthtech Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Influx Healthtech Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Influx Healthtech Ltd

Influx Healthtech Limited was originally incorporated on September 28, 2020 as a Private Limited Company as 'Influx Healthtech Private Limited' with the Registrar of Companies, Central Registration Centre.
Company converted from a Private Limited to Public Limited and the name of Company was changed to Influx Healthtech Limited' and a Fresh Certificate of Incorporation upon the conversion was issued on May 23, 2022 by the Registrar of Companies, Mumbai. Influx Healthtech Limited is a a Mumbai-based healthcare product-focused company that has carved a niche in manufacturing Soft Gelatin, Tablets, Capsules, Liquid Orals, Oral Powders, Liquid fill capsules, Effervescent tablets, Nutra Pallets, Protein Bars, Cookies, Jellies/ Gummies, External preparations like Creams, Gels, Ointments, External Oils, Soaps, etc.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Influx Healthtech Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Influx Healthtech Ltd or Sanofi India Ltd?

Market cap of Influx Healthtech Ltd is 672 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Influx Healthtech Ltd and Sanofi India Ltd?

The stock performance of Influx Healthtech Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Influx Healthtech Ltd and Sanofi India Ltd?

As of May 18, 2026, the Influx Healthtech Ltd stock price is INR ₹290.5. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Influx Healthtech Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Influx Healthtech Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.